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Background: Impaired cardiac function and sleep-disordered breathing (SDB) are associated
with progression of chronic kidney disease (CKD) in heart failure (HF) patients. Adaptive
servo-ventilation (ASV) therapy improves cardiac function in HF patients regardless of the
SDB severity through hemodynamic support and prevention of repetitive hypoxic stress. This
study was designed to test the hypothesis that ASV therapy improves renal function in HF
patients with SDB.
Methods and results: Of 59 consecutively enrolled HF patients, 43 with moderate-to-severe
SDB underwent ASV therapy. HF patients were divided into the ASV-treated group (n Z 27)
and the non-ASV-treated group (nZ 16). Estimated glomerular filtration rate (eGFR), echocar-
diographic parameters, and inflammatory biomarkers were measured before and 12 months
after ASV initiation. Improvement in the eGFR was found in the ASV-treated group, but not
in the non-ASV-treated group. There was a positive correlation between the increases in eGFR
and left ventricular ejection fraction (rZ 0.488, pZ 0.001). The changes in high-sensitivity C-
reactive protein were negatively correlated with change in the eGFR (rZ 0.416, pZ 0.006).
Conclusions: ASV therapy could improve renal dysfunction in HF patients through hemody-
namic support. Additionally, prevention of SDB with the use of ASV therapy could exert anti-
inflammatory effects, which could contribute to the improvement of renal function in HF
patients.
ª 2011 Elsevier Ltd. All rights reserved.8 884 6110; fax: þ81 18 836 2612.
ita-u.ac.jp (H. Ito).
1 Elsevier Ltd. All rights reserved.
Effects of ASV on CKD in HF patients 1947Introduction
Chronic kidney disease (CKD) is highly prevalent and closely
associated with a high mortality rate in heart failure (HF)
patients.1 Some mechanistic links between HF and CKD
have been proposed; for instance, low cardiac output under
HF conditions elicits prerenal insufficiency.2 The develop-
ment of novel therapeutic approaches for HF patients with
CKD is desirable.
Sleep-disordered breathing (SDB) is highly prevalent and
also contributes to poor prognosis in HF patients.3 The
presence of SDB enhances inflammatory responses due to
repetitive hypoxic responses, leading to impairment of
renal functions and progression of CKD. Impaired kidney
function enhances the activity of the sympathetic nervous
system and the renin-angiotensin-aldosterone system.2,4
Therefore, the cessation of this vicious cycle could be an
important therapeutic target in HF patients with CKD.
Adaptive servo-ventilation (ASV) (Autoset CS, ResMed,
Sydney, Australia) automatically adjusts its settings based on
an analysis of the patient’s breathing effort and maintains
steady minute ventilation without hemodynamic disadvan-
tages in HF patients. The ASV device prevents unstable
breathing and increases in preload while HF patients are in
the supine position. Our previous studies have shown the
beneficial effects of ASV in patients with HF. First, ASV
treatment increased cardiac function in HFpatientswith SDB
by preventing the inflammatory response caused by repeti-
tive cessation of breath.5 Second, ASV therapy improves the
short-term prognosis of HF patients and cardiac pump
function regardless of the severity of SDB.6 Therefore,
improvement of cardiac function and prevention of hypoxic
responses by ASV therapy could increase renal functions in
HF patients. This study was designed to test the hypothesis
that ASV therapy could improve renal function in patients
with HF by increasing the cardiac pump function and inhib-
iting repetitive cessation of breathing.
Methods
Study population
This study enrolled 59 consecutive HF patients (New York
Heart Association [NYHA] functional class II or III). Renal
function was measured based on the estimated glomerular
filtration rate (eGFR). The eGFR value was calculated
using the equation of the modification of the diet in
renal disease study, which was arranged for Japanese
individuals and recommended by the Japanese Society of
Nephrology.7 The eGFR (ml/min/1.73 m2) Z 194  [serum
creatine]1.094  [age]0.287  [0.739 if patient is female].
CKD was defined as an eGFR of <60 ml/min/1.73 m2. These
patients were referred for overnight polysomnography
(PSG) to screen for SDB at our sleep center of Akita
University Hospital. All patients provided written informed
consent regarding the PSG analysis and the ASV therapy. A
previous study showed that 43% of HF patients undergoing
continuous positive airway pressure (CPAP) therapy did not
experience reduced AHI score.8 The ASV therapy could
eliminate SDB events effectively when compared to CPAP
therapy.9 Based on these reports, an ASV device was usedto treat of HF with SDB and CKD in this study. This study was
approved by the clinical research and ethics committee of
the University of Akita. Patients were included in this study
for the following reasons: (1) a hospital admission history
due to worsening HF in the 6 months prior to therapy
initiation, and (2) CHF with an ejection fraction below 55%
as measured by ultrasonic echocardiography. Patients with
infectious disease, pharyngeal disease, or decompensated
HF, and those who had recovered from acute HF were
excluded from this study.
Study design
The 59 enrolled HF patients were divided into two groups
according to the severity of their SDB. The first group con-
sisted of HF patients whose apnea hypopnea index (AHI)
score was 15/h (patients with moderate-to-severe SDB,
nZ 43); the second group consisted of HF patients whose AHI
score was <15/h (patients with non-to-mild SDB, n Z 16).
ASV therapy was initiated for the patients withmoderate-to-
severe SDB after admission. The patients were fitted with an
ASV device, and the determination was made as to whether
they would receive ASV treatment during the initial 3 days of
their admission. Some patients refused ASV treatment
because of the discomfort of wearing a mask or because of
the positive airway pressure. Consequently, the patients
with moderate-to-severe SDB were divided into 2 groups: (1)
those receiving ASV treatment (ASV-treated patients;
nZ 27) and (2) those not receiving ASV treatment (non-ASV-
treated patients; nZ 16). ASV therapy was initiated the day
after conventional PSG by experienced physicians. Biophys-
icalmarkers (high-sensitivity C-reactive protein [hs-CRP] and
plasma brain natriuretic peptide [BNP]) were evaluated, and
echocardiographic parameters and eGFR were measured
before and after the 12-month ASV treatment in both groups.
Prescriptions for the enrolled patients were unchanged
during the follow-up period. If enrolled patients experienced
a decrease in blood pressure (systolic blood pressur-
e < 100 mmHg) or increased blood pressure (systolic blood
pressure> 140mmHg), calciumantagonists or diureticswere
decreased or added by half-increments. Additionally, if HF
patients experienced a minimum of 3 kg body weight
decrease or a minimum of 3 kg body weight increase,
diuretics were decreased or added, respectively by half-
increments. The angiotensin-converting enzyme inhibitor
or angiotensin receptor blocker doses were not changed
during the follow-up period due to their strong effect on
renal function.
Sleep study
Enrolled patients underwent overnight PSG monitoring
using the ProFusion PSG Sleep Diagnostic System (Com-
pumedics, Victoria, Australia), which continuously acquires
the data of an electroencephalogram, electrooculogram,
oxygen saturation (SaO2), airflow, snoring, and thor-
acoabdominal motion. Apnea was defined as an absence of
inspiration for 10 s, and obstructive apnea was distin-
guished from the central type by analyzing chest and
abdominal motions. Hypopnea was defined as a 30%
reduction in monitored airflow accompanied by a decrease
1948 T. Koyama et al.in SaO2 of4%. Arousal responses were defined according to
the recommendations of the American Sleep Disorders
Association. The AHI was defined as the number of apnea
and hypopnea episodes per hour during sleep. An AHI score
of 5/h was defined as SDB. A diagnosis of moderate-to-
severe SDB was assigned an AHI of 15/h, and non-to-mild
SDB was assigned an AHI of <15/h. A diagnosis of central
sleep apnea was assigned to an AHI>15/h, with>50% of the
events labeled as the central type rather than the
obstructive type of apnea.ASV treatment
After the PSG analysis, each patient selected a mask and
was trained by an experienced sleep technician on the
principles and use of the ASV system (Autoset CS;
ResMed). Adjustments were made by physicians who were
familiar with ASV treatment. An expiratory positive airway
pressure of approximately 5 cm H2O and an inspiratory
pressure support between 3 and 10 cm H2O were used. Over
the first 20 min of treatment, the patient’s heart rate,
SaO2, and blood pressure were monitored and observed
every 5 min. The ASV-treated patients were defined as
those whose device usage was >4 h per night during the
follow-up period. Compliance data were downloaded from
the ASV device and checked monthly in the outpatient
clinic. Patients with insufficient ASV use during sleep were
entered into the non-ASV group. These patients were
observed without ASV treatment during the follow-up
period.Echocardiography
Two-dimensional, M-mode, and Doppler echocardiography
(iE33; Philips Medical Systems, Andover, MA, USA) were
performed to evaluate various parameters of heart function
in the patients. The left ventricular ejection fraction (LVEF)
was determined from an apical 4-chamber view using
Simpson’s method. The sonographers were blinded to the
PSG results and were not involved in the treatment of these
patients.Statistical analysis
Continuous variables are expressed as the
mean  standard deviation. For continuous and normally
distributed data, Student’s t-test was used for compari-
sons between groups; for non-normally distributed data,
the ManneWhitney U-test was used. Correlations were
analyzed using Pearson’s correlation coefficient. Stepwise
multiple linear regression analyses were used to identify
the influential parameters for the eGFR changes. All
parameters with p < 0.10 in the univariate analyses were
entered into the multivariate analysis. A p value of <0.05
was considered statistically significant. All statistical
analyses were performed with SPSS for Windows ver. 16.0
(SPSS, Chicago, IL, USA).Results
Baseline characteristics of the enrolled 59 HF patients are
summarized in Table 1. AHI score ([patients with moderate-
to-severe SDB] 32.3  17.2 vs. [those with non-to-mild SDB]
10.2  3.6, p < 0.001), hypopnea events ([patients with
moderate-to-severe SDB] 18.5 10.0 vs. [those with non-to-
mild SDB] 5.1 2.7, p< 0.001), arousal index ([patients with
moderate-to-severe SDB] 30.5 15.9 vs. [those with non-to-
mild SDB] 19.3  6.4, p < 0.001), and hs-CRP levels
([patients with moderate-to-severe SDB] 0.24  0.17 mg/dl
vs. [those with non-to-mild SDB] 0.16  0.14 mg/dl,
p Z 0.036) were higher, whereas eGFR ([patients with
moderate-to-severe SDB] 44.3  12.7 ml/min/1.73 m2 vs.
[those with non-to-mild SDB] 52.8  11.9 ml/min/1.73 m2,
pZ 0.033) was lower in HF patients experiencing moderate-
to-severe SDB. The eGFR in each HF patient with moderate-
to-severe SDB was less than 60 ml/min/1.73 m2.
ASV therapy was initiated in patients with moderate-to-
severe SDB. Consequently, 27 patients agreed to continue
ASV treatment (ASV-treated patients) and successfully
underwent ASV during the 12-month follow-up period,
whereas 16 patients declined the therapy (non-ASV-treated
patients) or had insufficient ASV use because of mask
intolerance (n Z 9) or subjective intolerance to positive
airway pressure (nZ 7). The baseline characteristics in HF
patients with or without ASV therapy are demonstrated in
Table 2. No significant differences were found in either
group. In the moderate-to-severe SDB group, 67% under-
going the ASV therapy were diagnosed with predominant
central sleep apnea. Various parameters, including labo-
ratory data, echocardiographic findings, and eGFR were
recorded before and 12 months after ASV treatment. The
non-ASV-treated patients were also observed, and the same
parameters were measured.
No patient experienced potential complications or
changed the study protocol during the follow-up period.
Before ASV treatment, no significant differences were
observed in mean age, gender ratio, the prevalence of
structural heart disease, pharmacological treatment
(angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers, b-blockers, diuretics, aldosterone
antagonists, or statins), echocardiographic parameters, PSG
data, or laboratory data between the two groups. The ASV-
treated patients continued ASV treatment during the follow-
up period after their hospital stay. The mean ASV device use
timewas 5.8 0.8 h in patients undergoing ASV therapy. The
non-ASV-treated patients were also observed during the
follow-up period. Two patients (7.2%) in the ASV-treated
patients, and one patient (6.2%) in the non-ASV-treated
patients experienced increased doses of calcium antago-
nists, whereas one patient (3.7%) had a case of a dis-
continued calcium antagonist in the ASV-treated patients
and one patient (6.2%) had a case of discontinued use of
a calcium antagonist in the non-ASV-treated patients. Each
patient (ASV-treated patients; 3.7%, non-ASV-treated
patients; 6.2%) experienced increased doses of diuretics,
whereas two patients (7.2%) experienced a decreased dose
of diuretics in the ASV-treated patients and one patient
(6.2%) was given a decreased dose of diuretics in the non-
ASV-treated patients.
Table 1 Baseline characteristics of the enrolled HF patients.
All patients (N Z 59) moderate-to-severe
SDB-patients (N Z 43)
non-to-mild
SDB-patients (N Z 16)
P Value
Age, years 74.1  8.3 75.0  7.1 71.5  10.5 0.257
Male sex, n (%) 49 (83.1) 36 (83.7) 13 (81.3) 0.823
BMI, kg/m2 23.8  3.7 23.4  3.1 24.9  4.9 0.145
NYHA class II, n (%) 34 (57.6) 24 (55.8) 10 (62.5) 0.770
Hypertension, n (%) 50 (84.7) 38 (88.4) 12 (75.0) 0.236
Diabetes mellitus, n (%) 16 (27.1) 10 (23.3) 6 (37.5) 0.329
Hyperlipidemia, n (%) 19 (32.2) 12 (27.9) 7 (43.7) 0.348
Underlying heart disease, n (%)
Ischemic heart disease 17 (28.8) 11 (25.6) 6 (37.5) 0.519
Valvular heart disease 13 (22.0) 10 (23.3) 3 (18.8) 0.707
Cardiomyopathy 18 (30.5) 11 (25.6) 7 (43.8) 0.212
Heart rhythm disorder, n (%)
Atrial fibrillation 24 (40.7) 19 (41.2) 5 (31.3) 0.552
Pacemaker 17 (28.8) 11 (25.6) 6 (37.5) 0.519
Blood pressure
Systolic, mmHg 115.8  16.7 116.1  16.4 115.1  18.0 0.785
Diastolic, mmHg 63.5  10.6 63.1  9.8 64.6  12.9 0.864
Heart rate,/min 66.4  8.4 65.9  8.4 67.6  8.5 0.599
Medication, n (%)
ACEIs/ARBs 57 (96.6) 42 (97.7) 15 (93.8) 0.472
b-blockers 46 (78.0) 32 (74.4) 14 (87.5) 0.481
Aldosterone antagonists 37 (62.7) 28 (65.1) 9 (56.3) 0.558
Diuretics 37 (62.7) 28 (65.1) 9 (56.3) 0.558
Ca antagonists 30 (50.8) 21 (48.8) 9 (56.3) 0.771
Statins 27 (45.8) 18 (41.9) 9 (56.2) 0.386
Polysomnography data
AHI, n/h 26.4  17.7 32.3  17.2 10.2  3.6 <0.001
Central, n/h 5.6  10.1 6.9  10.5 2.3  2.6 0.066
Obstructive, n/h 4.5  10.7 5.2  12.3 2.4  3.3 0.411
Hypopnea, n/h 14.9  10.5 18.5  10.0 5.1  2.7 <0.001
Mean SaO2, % 94.0  2.2 94.1  2.4 93.8  1.6 0.683
Arousal index, n/h 27.4  14.8 30.5  15.9 19.3  6.4 <0.001
Total Sleep Time, h 5.1  1.0 5.1  1.0 5.2  1.0 0.585
Echocardiography data
LVEF (%) 43.9  9.1 44.4  7.8 42.5  11.9 0.979
Laboratory data
eGFR (ml min1 1.73 m2) 46.6  12.5 44.3  12.7 52.8  9.97 0.032
hs-CRP levels (mg/dl) 0.22  0.16 0.24  0.17 0.16  0.14 0.036
Plasma BNP levels (pg/ml) 269.1  301.4 292.8  328.3 205.3  208.4 0.261
Values are reported as mean  standard deviation.
HF Z heart failure; SDB Z sleep-disordered breathing; BMI Z body mass index; ACEIs Z angiotensin-converting enzyme inhibitors;
ARBs Z angiotensin receptor blockers; AHI Z apnea hypopnea index; SaO2 Z oxygen satuation; LVEF Z left ventricular ejection
fraction; eGFR Z estimated glomerular filtration rate; hs-CRP Z high-sensitivity C-reactive protein, BNP Z brain natriuretic peptide.
Effects of ASV on CKD in HF patients 1949The eGFR changes of the two groups before and 12
months after ASV treatment are compared in Fig. 1 (Fig. 1,
left; ASV-treated patients; Fig. 1, right; non-ASV-treated
patients). The eGFR increased significantly in the ASV-
treated group (44.2  12.3 ml/min/1.73 m2 to
48.2  12.9 ml/min/1.73 m2, pZ 0.0095), but significantly
decreased in the non-ASV-treated patients (44.7  13.7 ml/
min/1.73 m2 to 38.3  14.4 ml/min/1.73 m2, p Z 0.0052).
The levels of eGFR at 12 months after ASV therapy were
significantly elevated in the ASV-treated patients when
compared to the non-ASV-treated patients (48.2  12.9 vs.
38.3  14.4 ml/min/1.73 m2, p Z 0.0253).The LVEF changes before and 12 months after ASV
therapy are shown in Fig. 2. An increased LVEF was
observed in ASV-treated patients (Fig. 2, left; 43.5  6.9%
to 48.0  6.5%, p < 0.0001), whereas a significant
decreased LVEF changes were shown in non-ASV-treated
patients (Fig. 2, right; 46.1  9.2% to 43.8  9.2%,
pZ 0.0037). Additionally, the LVEF of ASV-treated patients
at 12 months after the therapy was significantly higher
when compared to that of non-ASV-treated patients
(48.0  6.5% vs. 43.8  9.2%, p Z 0.0322, respectively).
The reduced hs-CRP levels were observed in ASV-treated
patients (0.22  0.13 to 0.06  0.04 mg/dl, p < 0.001),
Table 2 Baseline characteristics of the HF patients with moderate-to-severe SDB.
All patients (N Z 43) ASV-treated
patients (N Z 27)
non-ASV-treated
patients (N Z 16)
P Value
Age, years 75.0  7.1 74.8  7.6 75.4  6.4 0.785
Male sex, n (%) 36 (83.7) 23 (85.2) 13 (81.3) 0.473
BMI, kg/m2 23.4  3.1 23.4  3.1 23.3  3.2 0.937
NYHA class II, n (%) 24 (55.8) 16 (59.3) 8 (50.0) 0.565
Hypertension, n (%) 38 (88.4) 25 (92.6) 13 (81.3) 0.326
Diabetes mellitus, n (%) 10 (23.3) 6 (22.2) 4 (25.0) 0.840
Hyperlipidemia, n (%) 12 (27.9) 7 (25.9) 5 (31.3) 0.715
Underlying heart disease, n (%)
Ischemic heart disease 11 (25.6) 6 (22.2) 5 (31.3) 0.523
Valvular heart disease 10 (23.3) 7 (25.9) 3 (18.8) 0.601
Cardiomyopathy 11 (25.6) 6 (22.2) 5 (31.3) 0.523
Heart rhythm disorder, n (%)
Atrial fibrillation 19 (41.2) 11 (40.7) 8 (50.0) 0.565
Pacemaker 11 (25.6) 5 (18.5) 6 (37.5) 0.206
Blood pressure
Systolic, mmHg 116.1  16.4 117.0  14.2 114.6  20.0 0.643
Diastolic, mmHg 63.8  9.9 62.3  10.8 66.3  7.7 0.206
Heart rate,/min 65.9  8.4 65.8  8.5 66.1  8.6 0.751
Medication, n (%)
ACEIs/ARBs 42 (97.7) 27 (100) 15 (93.8) 0.333
b-blockers 32 (74.4) 18 (66.7) 14 (87.5) 0.106
Aldosterone antagonists 28 (65.1) 16 (59.3) 12 (75.0) 0.307
Diuretics 28 (65.1) 16 (59.3) 12 (75.0) 0.307
Ca antagonists 21 (48.8) 13 (48.1) 8 (50.0) 0.909
Statins 18 (41.9) 10 (37.0) 8 (50.0) 0.424
Polysomnography data
AHI, n/h 32.3  17.2 32.2  17.1 32.4  17.8 0.979
Central, n/h 6.9  10.5 5.5  9.3 9.3  11.4 0.571
Obstructive, n/h 5.2  12.3 5.7  13.0 4.5  11.3 0.781
Hypopnea, n/h 18.5  10.0 19.3  10.1 17.3  10.2 0.497
Mean SaO2, % 94.1  2.4 94.0  2.5 94.2  2.1 0.705
Arousal index, n/h 30.5  15.9 30.9  15.6 29.8  16.9 0.824
Total Sleep Time, h 5.1  1.0 5.1  1.2 5.0  0.8 0.783
Echocardiography data
LVEF (%) 44.4  7.8 43.5  6.9 46.1  9.2 0.341
Laboratory data
hs-CRP levels (mg/dl) 0.24  0.17 0.22  0.13 0.28  0.21 0.269
Plasma BNP levels (pg/ml) 292.8  328.3 334.8  389.0 222.0  176.3 0.547
Values are reported as mean  standard deviation.
HFZ heart failure; SDBZ sleep-disordered breathing; ASVZ adaptive servo-ventilation; BMIZ body mass index; ACEIsZ angiotensin-
converting enzyme inhibitors; ARBs Z angiotensin receptor blockers; AHI Z apnea hypopnea index; SaO2 Z oxygen satuation;
LVEF Z left ventricular ejection fraction; hs-CRP Z high-sensitivity C-reactive protein, BNP Z brain natriuretic peptide.
1950 T. Koyama et al.but not in non-ASV-treated patients (0.28  0.21 to
0.30  0.24 mg/dl, p Z 0.117). The hs-CRP levels of ASV-
treated patients at 12 months after the therapy initiation
were reduced when compared to non-ASV-treated patients
(0.06  0.04 vs. 0.30  0.24 mg/dl, p < 0.001, respec-
tively). No body weight (BW) or body mass index (BMI)
changes were observed in either group during the follow-up
period (ASV-treated patients: [BW] 62.0  8.1 to
61.5  7.8 kg, p Z 0.344, [BMI] 23.4  3.1 to 23.2  3.0,
p Z 0.369, non-ASV-treated patients: [BW] 63.1  10.1 to
62.4  9.6 kg, p Z 0.195, [BMI] 23.3  3.2 to 23.1  3.0,
p Z 0.242, respectively).Fig. 3 shows the correlation between LVEF changes and
eGFR changes in patients with CHF accompanied by CKD.
The changes in eGFR and the changes in LVEF were posi-
tively correlated in patients with HF (rZ 0.488, pZ 0.001,
R2 Z 0.283). Fig. 4 shows the relationship between the
change in eGFR and hs-CRP levels in those patients with
CHF accompanied by CKD; these were negatively correlated
(r Z 0.416, p Z 0.006, R2 Z 0.273). In the stepwise
multiple linear regression analysis including ASV therapy
use, changes in LVEF, and changes in hs-CRP levels, the ASV
device use was the most influential parameter on the
improvement of changes in eGFR (b Z 0.529, standard
p = 0.0253 
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Figure 1 Comparison of the eGFR before and 12 months after
ASV initiation in HF patients with or without ASV therapy. ASV-
treated patients; n Z 27, non-ASV-treated patients; n Z 16.
eGFRZ estimated glomerular filtration rate, HFZ heart failure,
ASVZ adaptive servo-ventilation.
Figure 3 Correlation between the changes in eGFR and the
changes in LVEF in patients with HF accompanied by CKD. Open
dots; ASV-treated patients (n Z 27), filled dots; non-ASV-
treated patients (n Z 16). eGFR Z estimated glomerular
filtration rate, LVEF Z left ventricular ejection fraction,
HF Z heart failure, CKD Z chronic kidney disease.
Effects of ASV on CKD in HF patients 1951errorZ 2.620, p < 0.001). The duration of daily ASV use did
not affect the changes in eGFR (bZ 0.189, pZ 0.345) or
the LVEF changes (b Z 0.194, p Z 0.351).
Discussion
This study provides several major insights into SDB as
a therapeutic target in HF patients with renal dysfunction.
First, the value of eGFR was significantly lower in HF
patients with moderate-to-severe SDB, as compared with
that in patients with non-to-mild SDB. This result suggests
that the prevalence of SDB might be a contributor to renal
dysfunction in HF patients (Table 1). Second, the 12-month
ASV treatment improved the eGFR value in HF patients with
SDB (Fig. 1). Third, the changes in the LVEF were positivelyp= 0.0322
p= 0.0037p <0.0001
n.s.
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Figure 2 Comparison of the LVEF before and 12 months after
ASV initiation in HF patients with or without ASV therapy. ASV-
treated patients; n Z 27, non-ASV-treated patients; n Z 16.
LVEF Z left ventricular ejection fraction, HF Z heart failure,
ASV Z adaptive servo-ventilation.correlated with the changes in eGFR (Fig. 3), implying that
the improvement in the LVEF by ASV therapy (Fig. 2) could
lead to increased renal perfusion in HF patients with CKD.
Finally, the changes in serum hs-CRP levels were negatively
correlated with the changes in eGFR. It is likely that ASV
therapy could improve renal function by preventing
inflammatory responses, which might be associated with
SDB (Fig. 4).
It has previously been reported that the prevalence of
CKD is associated with poor prognosis in HF patients.1 The
low cardiac output due to HF leads to reduced renal
perfusion,10 endothelial dysfunction,11 and systemic
inflammation,12 resulting in the development and progres-
sion of CKD.2 A pharmacological approach, such as the use
of diuretics, could also be a contributing factor for wors-
ening renal dysfunction in HF patients.10 Renal damage
causes the stimulation of sympathetic nerve activity,
enhancement of the renin-angiotensin-aldosterone system,
and the progression of anemia, resulting in decreasing
cardiac functions and worsening of the prognosis in HF
patients.2 Therefore, the prevention of this vicious cycle
could be an important therapeutic approach for HF patients
with CKD. Despite the fact that the development ofFigure 4 Correlation between the changes in LVEF and the
changes in hs-CRP levels in patients with HF accompanied by
SDB. Open dots; ASV-treated patients (n Z 27), filled dots;
non-ASV-treated patients (n Z 16). LVEF Z left ventricular
ejection fraction, hs-CRPZ high-sensitivity C-reactive protein,
HF Z heart failure, SDB Z sleep-disordered breathing.
1952 T. Koyama et al.pharmacological and non-pharmacological therapy for CHF
has improved the prognosis in HF patients, the presence of
CKD still contributes to a high mortality rate, even in HF
patients who have undergone these pharmacological and
non-pharmacological therapies.1,13
It was recently reported that ASV therapy improves both
the cardiac pump function without hemodynamic disad-
vantages and the prognosis in HF patients, regardless of the
severity of SDB.6 This result provided a novel therapeutic
paradigm in that ASV therapy could be part of a hemody-
namic support system in HF patients. In this study, the
changes in LVEF were positively correlated with the
changes in eGFR, indicating that improvements in cardiac
pump function could be associated with the increase of
renal function in HF patients with CKD (Fig. 3). It is likely
that renal perfusion is increased by ASV therapy. Elevated
sympathetic nerve activities in the failing heart could play
an important role in the development and progression of
CKD.4 Another considerable reason for the improvement of
renal function by ASV therapy is the prevention of sympa-
thetic nerve activity. A recent study demonstrated that ASV
therapy could immediately decrease sympathetic nerve
activity in HF patients.14 Further studies are needed to
clarify the causative relationship between the reduction of
sympathetic nerve activity by the ASV therapy and the
improvement of renal function.
ASV therapy improves cardiac function and performance
states in HF patients with SDB by preventing inflammatory
responses.5 Repetitive hypoxic stress caused by SDB could
induce systemic inflammation,5 increased sympathetic
nerve activitiy15 and endothelial dysfunction, and subse-
quent renal damage could develop in these patients. It is
known that proinflammatory cytokines can impair renal
function.16 In the present study, changes in hs-CRP levels
were negatively correlated with changes in eGFR (Fig. 4).
The reduction in serum hs-CRP levels may be a surrogate
marker for the improvement of inflammatory responses
induced by SDB. This result implies that ASV therapy
improves renal function by preventing hypoxic stress caused
by SDB. Inhibition of SDB by ASV therapy could be a novel,
important therapeutic option in HF patients with CKD.
Limitations of this study are as follows; first, the serum
levels of cytokines such as interleukin-6 and tumor necrosis
factor-a in order to assess the systemic proinflammatory
responses caused by HF and repetitive hypoxia were not
evaluated in this study. Second, sympathetic nerve activity
was not examined in this study. Therefore, direct rela-
tionships between the improvement of renal function and
the inflammatory response or sympathetic nerve activity
were not clarified in this study. Third, other factors
including better adherence to drug treatment may
contribute to the improved renal function in ASV-treated
patients. Fourth, this study could not show the prognosis of
HF patients with CKD. Further randomized studies are
needed to resolve these limitations.
In conclusion, ASV therapy could improve renal function
by the improvement of cardiac function and prevention of
SDB in patients with HF accompanied by CKD. The poly-
modal beneficial effects of ASV therapy constitute useful
non-pharmacological therapeutic approaches to the treat-
ment of HF patients with CKD, and could improve the
prognosis of HF patients.Supplementary material
Supplementary material associated with this article can be
found, in the online version, at doi:10.1016/j.rmed.2011.
09.001.
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